Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced its participation in two investor conferences aimed at addressing unmet medical needs. The events include the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021 (on-demand presentations) and The Benchmark Company Healthcare House Call Virtual Conference on May 26, 2021 (one-on-one meetings). Processa focuses on developing treatments for conditions such as metastatic colorectal cancer, breast cancer, and GI motility disorders. The company aims to enhance patient survival and quality of life through existing clinical evidence.
- None.
- None.
HANOVER, MD., May 18, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced today that management will participate in two upcoming investor conferences:
Oppenheimer Rare & Orphan Disease Summit
| ● | May 21, 2021 (On demand presentation for registered participants and available for 1x1 meetings) | |
| https://www.oppenheimer.com/events/2021/rare-orphan-disease-summit.aspx |
The Benchmark Company Healthcare House Call Virtual Video 1x1 Investor Conference
| ● | May 26, 2021 (one-on-one meetings only) | |
| https://www.benchmarkcompany.com/news-events/upcoming-events |
To schedule a one-on-one meeting with management, please contact your conference representative or James@HaydenIR.com.
About Processa Pharmaceuticals, Inc.
The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The Company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active clinical pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com.
Forward-Looking Statements
This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the registration statement relating to the securities being sold in this offering, which identifies important risk factors which could cause actual results to differ from those contained in the forward-looking statements.
For More Information:
Michael Floyd
mfloyd@processapharma.com
301-651-4256
James Carbonara
Hayden IR
(646) 755-7412
james@haydenir.com
FAQ
What are the details of Processa Pharmaceuticals' upcoming investor conferences in May 2021?
What is the focus of Processa Pharmaceuticals as mentioned in the May 2021 press release?
What notable pipeline programs does Processa Pharmaceuticals highlight in the press release?
How can investors schedule meetings with Processa Pharmaceuticals management during the conferences?
